Gilead Sciences Inc on Tuesday unveiled data from the first human study of its experimental oral COVID-19 antiviral, saying the results in healthy volunteers cleared the way for two large Phase III trials of the drug that have begun enrolling patients.
The drug, obeldesivir and previously known as GS-5245, is designed to keep the coronavirus that causes COVID from replicating in the body and overwhelming a patient's immune system. Once metabolized, it works in the same way as Gilead's older intravenous COVID treatment Veklury (remdesivir), which targets virus replication through inhibition of the viral RNA polymerase.
For standard risk patients, Gilead believes the new drug could help resolve symptoms earlier and is evaluating any association with symptoms of long COVID, Anu Osinusi, who oversees clinical research for hepatitis, respiratory and emerging viruses at Gilead, told Reuters.
"The WHO still calls this a global health emergency ... We are not seeing a surge, but the numbers are holding steady," she said of the World Health Organization.
The Phase I trial, which involved 70 healthy adults, showed that obeldesivir reached sufficient concentrations in the blood and supports taking it without regard to food, according to Gilead.
Two obeldesivir patients reported headache, as did one placebo patient. No serious side effects were reported.
The most common laboratory abnormality was grade 2 creatinine clearance decrease, which can be an indication of impaired kidney function and occurred in 31% of treated participants and 25% of placebo participants.
Gilead has advanced obeldesivir into two late-stage global studies for treating non-hospitalized COVID patients. One trial is enrolling vaccinated people with at least two risk factors for developing serious COVID and unvaccinated patients with at least one risk factor.
The other is enrolling COVID patients at standard risk of serious illness regardless of vaccination status.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.